- Home
- ADPT vs SKE Comparison
ADPT vs SKE Comparison
Compare ADPT & SKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- SKE
- Stock Information
- Founded
- ADPT 2009
- SKE 1979
- Country
- ADPT United States
- SKE Canada
- Employees
- ADPT N/A
- SKE N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- SKE Precious Metals
- Sector
- ADPT Health Care
- SKE Basic Materials
- Exchange
- ADPT Nasdaq
- SKE Nasdaq
- Market Cap
- ADPT 929.8M
- SKE 993.1M
- IPO Year
- ADPT 2019
- SKE N/A
- Fundamental
- Price
- ADPT $5.94
- SKE $9.44
- Analyst Decision
- ADPT Buy
- SKE
- Analyst Count
- ADPT 4
- SKE 0
- Target Price
- ADPT $6.50
- SKE N/A
- AVG Volume (30 Days)
- ADPT 1.4M
- SKE 329.9K
- Earning Date
- ADPT 02-12-2025
- SKE 11-14-2024
- Dividend Yield
- ADPT N/A
- SKE N/A
- EPS Growth
- ADPT N/A
- SKE N/A
- EPS
- ADPT N/A
- SKE N/A
- Revenue
- ADPT $177,282,000.00
- SKE N/A
- Revenue This Year
- ADPT $6.48
- SKE N/A
- Revenue Next Year
- ADPT $18.84
- SKE $50.00
- P/E Ratio
- ADPT N/A
- SKE N/A
- Revenue Growth
- ADPT N/A
- SKE N/A
- 52 Week Low
- ADPT $2.28
- SKE $3.29
- 52 Week High
- ADPT $7.07
- SKE $10.33
- Technical
- Relative Strength Index (RSI)
- ADPT 61.49
- SKE 55.45
- Support Level
- ADPT $5.98
- SKE $8.76
- Resistance Level
- ADPT $6.93
- SKE $9.60
- Average True Range (ATR)
- ADPT 0.45
- SKE 0.33
- MACD
- ADPT 0.03
- SKE 0.02
- Stochastic Oscillator
- ADPT 75.53
- SKE 69.73
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About SKE Skeena Resources Limited
Skeena Resources Ltd is a Canadian mining exploration company focused on developing prospective precious and base metal properties in the Golden Triangle of northwest British Columbia, Canada. The company's primary activity is the exploration and development of the past-producing Eskay Creek mine acquired from Barrick.